Solid Biosciences Inc SLDB:NASDAQ

Last Price$0.58NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change-0.04(6.43%)
Bid (Size)$0.53 (10)
Ask (Size)$0.62 (100)
Day Low / High$0.55 - 0.63
Volume1.3 M
 

View Biotechnology IndustryPeer Comparison as of 07/01/2022

 

Solid Biosciences Inc ( NASDAQ )

Price: $0.58
Change: -0.04 (6.43%)
Volume: 1.3 M
4:00PM ET 7/01/2022
 
 

ImmuCell Corp ( NASDAQ )

Price: $8.60
Change: -0.09 (1.04%)
Volume: 1.9 K
4:00PM ET 7/01/2022
 
 

Athersys Inc ( NASDAQ )

Price: $0.25
Change: -0.01 (5.54%)
Volume: 2.4 M
4:00PM ET 7/01/2022
 
 

Harpoon Therapeutics Inc ( NASDAQ )

Price: $1.88
Change: -0.03 (1.57%)
Volume: 112.1 K
4:00PM ET 7/01/2022
 
 

Atreca Inc ( NASDAQ )

Price: $1.79
Change: 0.00 (0.00%)
Volume: 95.8 K
4:00PM ET 7/01/2022
 

Read more news Recent News

Piper Sandler Adjusts Price Target on Solid Biosciences to $2 From $5, Maintains Neutral Rating
8:01AM ET 5/19/2022 MT Newswires

Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...

--Piper Sandler Adjusts Solid Biosciences' Price Target to $5 From $6, Maintains Neutral Rating
8:52AM ET 4/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--SVB Leerink Adjusts Price Target on Solid Biosciences to $12 From $5, Keeps Outperform Rating
8:52AM ET 4/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Chardan Research Adjusts Price Target on Solid Biosciences to $7 From $17 on Duchenne Muscular Dystrophy Market Assumptions, Reiterates Buy Rating
5:32AM ET 4/28/2022 MT Newswires

Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionSolid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA. View company web site for more details
Address500 Rutherford Avenue
Charlestown, Massachusetts 02129
Phone+1.617.337.4680
Number of Employees111
Recent SEC Filing06/09/20224
President, Chief Executive Officer & DirectorIlan Ganot
Chief Financial Officer & TreasurerStephen J. DiPalma
Chief Scientific OfficerCarl Morris
Senior VP, Head-Clinical DevelopmentRoxana Donisa Dreghici

Company Highlights

Price Open$0.62
Previous Close$0.62
52 Week Range$0.42 - 3.77
Market Capitalization$65.0 M
Shares Outstanding112.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.72
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-660.25%
Return on Equity-37.71%

Analyst Ratings as of 06/22/2022

Buy
2
Overweight
1
Hold
1
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset